Live Analyst Rating Changes 23245 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Vijay Kumar
EVR

Vijay Kumar

Evercore ISI
Wall Street Analyst
★★★★★
#171
on 13Foresight · ranked by our own returns
74%
Success Rate
+8.9%
Average Return
54 of 73 calls profitable · +3.3% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 74% of Vijay Kumar's ratings turned a profit when each position was held for 1 year — averaging +8.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

136 Buy 32 Hold 0 Sell
Vijay's Stock Coverage 33 ratings · 2026-08-12
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
IRTC
Irhythm Technologies
 Aug 07, 2026 BUY Strong Buy
+28.9% avg upside
20 analysts
$165.00
33.78% Upside
 -4.8% ·
ENOV
Enovis
 Aug 07, 2026 BUY Strong Buy
+172.7% avg upside
39 analysts
$32.00
31.11% Upside
 +0.0% ·
AZTA
Azenta
 Aug 06, 2026 BUY Buy
+46.2% avg upside
13 analysts
$35.00
4.50% Upside
 +8.4% ·
CAI
Caris Life Sciences, Inc.
 Aug 06, 2026 BUY Strong Buy
+19.9% avg upside
20 analysts
$26.00
10.70% Upside
 +11.3% ·
RVTY
Revvity
 Aug 05, 2026 BUY Buy
-6.4% avg upside
23 analysts
$126.00
9.09% Upside
 +0.9% ·
PRCT
PROCEPT BioRobotics
 Aug 05, 2026 BUY Buy
+42.8% avg upside
17 analysts
$23.00
5.87% Upside
 +10.7% ·
WAT
Waters
 Aug 05, 2026 BUY Strong Buy
-5.0% avg upside
31 analysts
$420.00
1.73% Upside
 +1.7% ·
AVTR
Avantor
 Jul 30, 2026 HOLD Buy
+12.6% avg upside
26 analysts
$14.00
2.57% Upside
 +0.5% ·
BLCO
Bausch + Lomb Corporation
 Jul 30, 2026 HOLD Buy
+18.5% avg upside
19 analysts
$17.00
0.93% Upside
 -0.9% ·
GEHC
GE Healthcare Technologies Inc
 Jul 30, 2026 BUY Strong Buy
+13.0% avg upside
22 analysts
$84.00
15.77% Upside
 +3.4% ·
BSX
Boston Scientific
 Jul 30, 2026 BUY Strong Buy
+32.8% avg upside
38 analysts
$55.00
9.81% Upside
 +7.2% ·
TMO
Thermo Fisher
 Jul 06, 2026 BUY Strong Buy
+0.2% avg upside
38 analysts
$570.00
4.51% Downside
 +15.9% ·
ZBH
Zimmer Biomet Holdings
 Jul 06, 2026 BUY Buy
+17.5% avg upside
38 analysts
$110.00
13.33% Upside
 +8.5% ·
PEN
Penumbra
 Jul 06, 2026 BUY Buy
+1.2% avg upside
23 analysts
$320.00
1.75% Downside
 +2.6% ·
GH
Guardant Health
 Jul 06, 2026 BUY Strong Buy
-1.1% avg upside
31 analysts
$200.00
18.37% Upside
 -3.0% ·
TWST
Twist Bioscience
 Jul 06, 2026 HOLD Strong Buy
-27.5% avg upside
14 analysts
$102.00
17.27% Downside
 +23.9% ·
SYK
Stryker
 Jul 06, 2026 BUY Strong Buy
+6.1% avg upside
37 analysts
$350.00
1.25% Upside
 +6.5% ·
ABT
Abbott Laboratories
 Jul 06, 2026 BUY Strong Buy
+5.2% avg upside
36 analysts
$112.00
2.26% Upside
 +14.4% ·
A
Agilent
 Jul 06, 2026 BUY Strong Buy
-0.2% avg upside
33 analysts
$148.00
0.06% Downside
 +14.0% ·
BAX
Baxter International
 Jul 06, 2026 BUY Buy
+21.2% avg upside
23 analysts
$24.00
12.74% Downside
 +21.7% ·
BDX
Becton Dickinson
 Jul 06, 2026 BUY Buy
+8.3% avg upside
25 analysts
$180.00
0.50% Upside
 +15.5% ·
DHR
Danaher
 Jul 06, 2026 BUY Strong Buy
+1.6% avg upside
45 analysts
$230.00
10.29% Upside
 +5.8% ·
EW
Edwards Lifesciences
 Jul 06, 2026 BUY Strong Buy
+7.8% avg upside
34 analysts
$100.00
8.27% Upside
 -2.1% ·
ILMN
Illumina
 Jul 06, 2026 BUY Buy
-8.8% avg upside
31 analysts
$200.00
4.51% Upside
 -1.7% ·
ISRG
Intuitive Surgical
 Jul 06, 2026 HOLD Strong Buy
+19.9% avg upside
36 analysts
$430.00
8.56% Upside
 -7.3% ·
MDT
Medtronic
 Jul 06, 2026 BUY Buy
+6.9% avg upside
38 analysts
$105.00
17.76% Upside
 +7.8% ·
MTD
Mettler-Toledo
 Jul 06, 2026 BUY Buy
-15.4% avg upside
18 analysts
$1350.00
5.22% Downside
 +11.0% ·
NVCR
NovoCure
 May 01, 2026 BUY Strong Buy
+182.8% avg upside
11 analysts
$20.00
15.63% Upside
 +4.9% ·
WST
West Pharmaceutical Services
 Feb 03, 2026 BUY Strong Buy
+4.4% avg upside
18 analysts
$320.00
8.77% Downside
 +34.1% ·
OSUR
Orasure Technologies
 May 19, 2025 HOLD Buy
+118.0% avg upside
11 analysts
$3.00
25.04% Downside
 +17.1% ·
MLAB
Mesa Laboratories
 Nov 12, 2024 BUY Strong Buy
+36.4% avg upside
5 analysts
$150.00
53.90% Upside
 -28.5% ·
HYPR
Hyperfine
 May 12, 2023 BUY Strong Buy
+114.1% avg upside
7 analysts
$2.50
156.17% Upside
 -44.8% ·
CEG
Constellation Energy Corporation
 Nov 09, 2022 BUY Strong Buy
+17.4% avg upside
30 analysts
$93.00
66.32% Downside
 +39.7% ·
🔒 28 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Vijay Kumar — Frequently Asked Questions
How accurate are Vijay Kumar's stock ratings?
Based on the calls 13Foresight could measure, about 72% of Vijay's ratings were profitable over a one-year hold, with an average return of +9.1% per rating, or +3.5% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Vijay ranked on 13Foresight?
Vijay Kumar is currently ranked #171 with a 5-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Vijay cover?
Vijay most recently has ratings on IRTC, ENOV, AZTA, CAI, RVTY, PRCT, WAT, AVTR, BLCO, GEHC, BSX, TMO and 21 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.